RxDoctor Payments Data

Linda Sheppard-Reece

Psychiatric/Mental Health · Pembroke, MANPI 1023495538

Payments from drug & device makers

$2,495in general payments, 2019–2025

Across 137 payments — averaging $18.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$557
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$431
  • Otsuka America Pharmaceutical, Inc.$275
  • Alkermes, Inc.$262
  • Johnson & Johnson$160
  • Sunovion Pharmaceuticals Inc.$126
  • plus $684 from 9 others

What the payments were for

  • Food & beverage$2,44898%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,495 in reported general payments places this provider in the 90th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

See all psychiatric/mental health providers in Massachusetts

Medicare billing

Part B allowed, 2024
$61,322
Medicare patients
119
Services billed
735

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate34$285,073
VraylarCariprazine Hcl30$73,088
Abilify MaintenaAripiprazole13$31,814
TrintellixVortioxetine Hydrobromide27$25,764
Invega SustennaPaliperidone Palmitate12$10,794
Adderall XrDextroamphetamine/Amphetamine11$6,937
VyvanseLisdexamfetamine Dimesylate11$4,535
Bupropion XlBupropion Hcl108$3,709
Eszopiclone12$3,451
KlonopinClonazepam13$3,323
Desvenlafaxine Succinate ErDesvenlafaxine Succinate27$2,658
Fluoxetine Hcl37$2,254
Trazodone Hcl95$1,666
Aripiprazole46$1,659
Sertraline Hcl130$1,482

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$101$285,07334 claims
AbbVieVraylar$557$73,08830 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$275$31,81413 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$77$30,29938 claims
Johnson & JohnsonInvega Sustenna$160$10,79412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

Other psychiatric/mental health in Pembroke

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →